TransAlta Signs Long-Term Agreement for 700 MW at Centralia Facility Enabling Coal to Natural Gas Conversion
December 09, 2025 07:00 ET | Source: TransAlta Corporation CALGARY, Alberta, Dec.…
Aeluma Files New Patent That Enhances Intellectual Property for Large-Scale High Performance Semiconductor Manufacturing
Strengthens Aeluma’s Heterogeneous Integration Platform and Expands Intellectual Property Portfolio to 35…
Zelluna ASA – Mandatory notification of trade
Reference is made to the private placement (the "Private Placement") and the retail…
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing…
Nelipak Acquires Merrills Packaging
CRANSTON, R.I., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak”), a…
Aurora Mobiles EngageLab Launches AI-Powered Customer Service Platform LiveDesk, Revolutionizing Enterprise Customer Experience
SHENZHEN, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:…
Mercury Showcases Expanding Portfolio of Electronic Warfare Capabilities at AOC 2025
December 08, 2025 07:00 ET | Source: Mercury Systems Inc ANDOVER, Mass.,…
The Acceleration Continues: Vetty Named One of Nucleus Researchs Hot Companies to Watch in 2026
AUSTIN, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vetty, the one-stop shop…
Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
